We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Biomarker Identifies Sarcopenia Patients with Excessive Neurotrypsin Activity

By LabMedica International staff writers
Posted on 07 Mar 2012
A novel biomarker was developed to identify the subgroup of patients (40%), whose sarcopenia is caused by excessive neurotrypsin activity. More...


The biomarker developed by Neurotune (Zurich, Switzerland), is the 22 kDa C-terminal agrin fragment (CAF). When agrin is inactivated by neurotrypsin, CAF is released and can be detected in the blood. Elevated levels of CAF are indicative of increased neurotrypsin activity and a measure of reduced neuromuscular junctions (NMJs) strength. The NTCAF enzyme-linked immunosorbent assay (ELISA) detects CAF in human serum.

Neurotrypsin regulates the strength of communication between nerve and muscle cells by cleaving and inactivating agrin. Excessive neurotrypsin activity causes deterioration of the synapses and subsequently muscle atrophy.

CAF is detectable in serum in healthy adults, aged between 20-75 years, defining a normal range. Approximately 40% of sarcopenia patients show statistically significant increased CAF levels above normal.

NTCAF ELISA was developed by Neurotune in collaboration with MicroCoat Biotechnologie GmbH (Bernried am Starnberger See, Germany), and the Eureka-Eurostars program (Brussels, Belgium). It is available immediately from Neurotune.

Neurotune is continuing to develop the ELISA assay as a marker of dysfunction of the neurotrypsin/agrin system in other pathological conditions.

Sarcopenia is a debilitating muscle disorder frequently affecting the elderly for which there is currently no cure. It is defined as loss of skeletal muscle mass and strength that occurs with advancing age. The current diagnosis of the disease is by dual-emission X-ray absorptiometry (DXA) scan, which measures lean body mass (LBM) in combination with functional tests. This cumbersome technique does not provide information on the underlying cause of loss of LBM.

It is estimated that sarcopenia currently affects over 50 million people worldwide and with the aging population this is expected to increase to over 200 million in the next 40 years.

Neurotune develops medications to treat disorders of the human nervous system. MicroCoat Biotechnologie is active in the field of immune and nucleic acid diagnostics. The purpose of the Eurostars Program is to provide funding for market-oriented research and development by small and medium-sized enterprises.

Related Links:

Neurotune
MicroCoat Biotechnologie GmbH
Eureka-Eurostars program




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.